pillbase.ru

Vitrakvi

Active substance: larotrectinib

larotrectinib sulfate

Centralised EU authorisationActive

Marketing holder: Bayer AG

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 7
  • VITRAKVI
    CAPSULE · LAROTRECTINIB 100 mg/1
    50419-391
    Bayer HealthCare Pharmaceuticals Inc.
  • VITRAKVI
    CAPSULE · LAROTRECTINIB 25 mg/1
    71777-390
    Loxo Oncology, Inc.
  • VITRAKVI
    CAPSULE · LAROTRECTINIB 25 mg/1
    50419-390
    Bayer HealthCare Pharmaceuticals Inc.
  • VITRAKVI
    SOLUTION, CONCENTRATE · LAROTRECTINIB 20 mg/mL
    50419-392
    Bayer HealthCare Pharmaceuticals Inc.
  • VITRAKVI
    SOLUTION · LAROTRECTINIB 20 mg/mL
    71777-392
    Loxo Oncology, Inc.
All products in this country (7)
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-6c4b-7f36-b62c-4a769162e6f5,01a1208d-b6a7-708f-af6f-829aa231eb41,01a12093-9744-79b1-9b31-3ad438b63e3b,01a12098-bcaa-7831-ac9a-ab94be027931,01a12099-acad-7083-b6e2-904e71f80e9f;count=7 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004919
Registration status
Active
ATC code
L01XE53
Sources
  • product · EMA · EMEA/H/C/004919 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004919 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004919 · Verified 2026-10-09